Users Online: 560 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 


RSACP wishes to inform that it shall be discontinuing the dispatch of print copy of JOACP to it's Life members. The print copy of JOACP will be posted only to those life members who send us a written confirmation for continuation of print copy.
Kindly email your affirmation for print copies to dranjugrewal@gmail.com preferably by 30th June 2019.

 

 
Table of Contents
LETTER TO EDITOR
Year : 2018  |  Volume : 34  |  Issue : 4  |  Page : 548

Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”


1 Global Medical Affairs, Pfizer Inc., New York, NY, USA
2 Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
3 Formerly of Pfizer Global Research and Development (Rinat), Pfizer Inc., South San Francisco, California, USA

Date of Web Publication3-Jan-2019

Correspondence Address:
Leslie A Tive
Pfizer Inc., 235 E 42nd St, New York, NY, 10017
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joacp.JOACP_155_18

Rights and Permissions

How to cite this article:
Tive LA, Viktrup L, Shelton D. Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”. J Anaesthesiol Clin Pharmacol 2018;34:548

How to cite this URL:
Tive LA, Viktrup L, Shelton D. Response to: “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis”. J Anaesthesiol Clin Pharmacol [serial online] 2018 [cited 2019 Aug 20];34:548. Available from: http://www.joacp.org/text.asp?2018/34/4/548/249292



Madam,

We read with interest the recently published review article by Patel et al. titled “Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.”[1] Tanezumab is under investigation for the treatment of osteoarthritis pain and chronic low back pain by Pfizer Inc. and Eli Lilly & Company. As Pfizer or Lilly were not involved or consulted regarding the content of this article, we would like to point out that the molecular formula of tanezumab presented in [Figure 1] is incorrect. For a more accurate representation of the structure of tanezumab, we refer readers to an article by La Porte et al.[2]

—On behalf of the tanezumab development team.

Financial support and sponsorship

Editorial support was provided by Matt Soulsby, PhD, CMPP, of Engage Scientific Solutions and was funded by Eli Lilly & Co and Pfizer.

Conflicts of interest

Leslie Tive is a full-time employee of, and own stock and/or stock options in, Pfizer Inc. David Shelton is a consultant for, and owns stock in, Pfizer Inc. Lars Viktrup is a full-time employee of, and owns stock and/or stock options in, Eli Lilly & Company.



 
  References Top

1.
Patel MK, Kaye AD, Urman RD. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol 2018;34:111-6.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
La Porte SL, Eigenbrot C, Ultsch M, Ho WH, Foletti D, Forgie A, et al. Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized fab-antigen complexes. MAbs 2014;6:1059-68.  Back to cited text no. 2
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed400    
    Printed8    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal